Rothschild Investment LLC Sells 258 Shares of Zoetis Inc. (NYSE:ZTS)

Rothschild Investment LLC decreased its position in Zoetis Inc. (NYSE:ZTS) by 8.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,829 shares of the company’s stock after selling 258 shares during the quarter. Rothschild Investment LLC’s holdings in Zoetis were worth $461,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ZTS. Callahan Advisors LLC lifted its position in Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after acquiring an additional 6,221 shares during the period. Pensionfund Sabic lifted its holdings in shares of Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after purchasing an additional 4,000 shares during the last quarter. PFW Advisors LLC bought a new stake in shares of Zoetis in the 4th quarter worth approximately $1,764,000. CIBC Asset Management Inc grew its stake in shares of Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after buying an additional 46,050 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Zoetis by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after buying an additional 279,092 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of several analyst reports. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Piper Sandler reduced their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $215.40.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Up 2.0 %

Shares of Zoetis stock opened at $168.60 on Wednesday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company’s 50 day moving average is $166.26 and its 200 day moving average is $177.66. The company has a market cap of $75.50 billion, a price-to-earnings ratio of 30.82, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.19%. Zoetis’s dividend payout ratio is currently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.